Little or no clinical evidence is available on the association between glucose exposure and peritoneal host defense in peritoneal dialysis (PD) patients. The objective of the present study was to quantify the exposure to glucose during the first year on PD and investigate the association with subsequent peritonitis.
Methods
We analyzed prospectively collected demographic and peritonitis data from incident adult PD patients between 1990 and 2010. For the present study, we conducted a review of both in- and outpatient medical records of all patients to obtain their day-to-day dialysis schemes during the first year on PD. From these data, the average exposure to glucose was quantified. The exposure was stratified into low- and high-glucose groups based on the median, analyzed per standard deviation and in quartiles. Cox proportional hazard models were used to calculate crude and adjusted hazard ratios (HRs) and 95% confidence intervals for the association between glucose exposure and peritonitis. Adjustments were made for age, sex, primary kidney disease, diabetes mellitus, Davies comorbidity score and the treatment period.
Results
In total, 230 patients were included in the study of whom 151 (66%) experienced a first peritonitis episode. The median follow-up time was 2.6 years (interquartile range [IQR]: 1.9 – 3.8) in the low-glucose group and 3.1 (IQR: 2.1 – 4.2) in the high-glucose group. After adjustment for confounding factors, no association between high glucose exposure and the risk of peritonitis was found (HR: 0.81; 0.55 – 1.17). No association was present when glucose exposure was analyzed per standard deviation (SD) (HR: 0.98; 0.79 – 1.21) or patient quartiles were applied. No association was identified between glucose exposure and severe peritonitis, Staphylococcus aureus peritonitis, or a peritonitis episode that lasted more than 14 days.
Conclusions
Exposure to glucose is not associated with an increased risk of peritonitis. The equilibrium between glycemic harm to peritoneal host defense and detrimental effects of glucose on invading microorganisms may determine the susceptibility to peritoneal infection.
KredietR.T., StruijkD.G.Peritoneal changes in patients on long-term peritoneal dialysis.Nat Rev Nephrol2013; 9: 419–29.
2.
TopleyN.Biocompatibility of peritoneal dialysis solutions and host defense.Adv Ren Replace Ther1996; 3: 309–11.
3.
JörresA.Innovative approaches to the preservation of the peritoneal membrane: from bench to bedside.Adv Ren Replace Ther2001; 8: 164–72.
4.
MortierS., LameireN.H., de VrieseA.S.The effects of peritoneal dialysis solutions on peritoneal host defense.Perit Dial Int2004; 24: 123–38.
5.
KazanciogluR.Peritoneal defense mechanisms—the effects of new peritoneal dialysis solutions.Perit Dial Int2009; 29: 198–201.
6.
ColesG.A., O'DonoghueD.J., PritchardN., OggC.S., JaniF.M., GokalR.A controlled trial of two bicarbonate-containing dialysis fluids for CAPD— final report.Nephrol Dial Transplant1998; 13: 3165–71.
7.
RippeB., SimonsenO., HeimburgerO., ChristenssonA., HaraldssonB., StelinG.Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Kidney Int2001; 59: 348–57.
8.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC.The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
9.
SzetoC.C., ChowK.M., LamC.W., LeungC.B., KwanB.C., ChungK.Y.Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products—a 1-year randomized control trial.Nephrol Dial Transplant2007; 22: 552–5.
10.
FanS.L., PileT., PunzalanS., RafteryM.J., YagoobM.M.Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function.Kidney Int2008; 73: 200–6.
11.
KimS., OhJ., KimS., ChungW., AhnC., KimS.G.Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.Nephrol Dial Transplant2009; 24: 2899–908.
12.
Haag-WeberM., KramerR., HaakeR., IslamM.S., PrischlF., HaugU.Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.Nephrol Dial Transplant2010; 25: 2288–96.
13.
SrivastavaS., HildebrandS., FanS.L.Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival.Kidney Int2011; 80: 986–91.
14.
JohnsonD.W., BrownF.G., ClarkM., BoudvilleN., EliasT.J., FooM.W.Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.J Am Soc Nephrol2012; 23: 1097–107.
15.
ParkS.H., DoJ.Y., KimY.H., LeeH.Y., KimB.S., ShinS.K.Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.Nephrol Dial Transplant2012; 27: 1191–9.
16.
ChoY., JohnsonD.W., BadveS.V., CraigJ.C., StrippoliG.F., WigginsK.J.The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients.Kidney Int2013; 84: 969–79.
17.
MontenegroJ., SarachoR., GallardoI., MartinezI., MunozR., QuintanillaN.Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis.Nephrol Dial Transplant2007; 22: 1703–8.
18.
GokalR., MistryC.D., PeersE.M.Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group: Multicenter Investigation of Icodextrin in Ambulatory Dialysis.Perit Dial Int1995; 15: 226–30.
19.
PosthumaN., ter WeeP., DonkerA.J., DekkerH.A., OeP.L., VerbrughH.A.Peritoneal defense using icodextrin and glucose for daytime dwell in CCPD patients.Perit Dial Int1999; 19: 334–42.
20.
ChowK.M., SzetoC.C., KwanB.C., PangW.F., MaT., LeungC.B.Randomized controlled study of icodextrin on the treatment of peritoneal dialysis patients during acute peritonitis.Nephrol Dial Transplant2014; 29: 1438–43.
21.
QiH., XuC., YanH., MaJ.Comparison of icodextrin and glucose solutions for long dwell exchange in peritoneal dialysis: a meta-analysis of randomized controlled trials.Perit Dial Int2011; 31: 179–88.
22.
DaviesS.J., PhillipsL., NaishP.F., RusselG.I.Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis.J Am Soc Nephrol2001; 12: 1046–51.
23.
Fernandez-ReyesM.J., BajoM.A., Del PesoG., OssorioM., DiazR., CarreteroB.The influence of initial peritoneal transport characteristics, inflammation, and high glucose exposure on prognosis for peritoneal membrane function.Perit Dial Int2012; 32: 636–44.
24.
DaviesS.J., RussellL., BryanJ., PhillipsL., RussellG.I.Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: their interrelationship and prediction of survival.Am J Kidney Dis1995; 26: 353–61.
25.
AmiciG., VirgaG., Da RinG., GrandessoS., VianelloA., GattiP.Serum beta-2-microglobulin level and residual renal function in peritoneal dialysis.Nephron1993; 65: 469–71.
26.
KredietR.T., BoeschotenE.W., ZuijderhoudtF.M.J., AriszL.The relationship between peritoneal glucose absorption and body fluid loss by ultrafiltration during continuous ambulatory peritoneal dialysis.Clin Nephrol1987; 27: 51–5.
27.
DaviesS.J., BryanJ., PhillipsL., RussellG.I.Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis.Nephrol Dial Transplant1996; 11: 498–506.
28.
VergerC., DumanM., DurandP.Y., VeniezG., FabreE., RyckelynckJ.P.Influence of autonomy and time of home assistance on the prevention of peritonitis in assisted automated peritoneal dialysis patients. An analysis of data from the French Language Peritoneal Dialysis Registry.Nephrol Dial Transplant2007; 22: 1218–23.
29.
BieberS.D., BurkartJ., GolperT.A., TeitelbaumI., MehrotraR.Comparative outcomes between continuous ambulatory and automated peritoneal dialysis: a narrative review.AJKD2014; 63: 1027–37.
30.
CooperR.A., MolanP.C., HardingK.G.The sensitivity to honey of gram-positive cocci of clinical significance isolated from wounds.J Appl Microbiology2002; 93: 857–63.
31.
CooperR.A., HalasE., MolanP.C.The efficacy of honey in inhibiting strains of Pseudomonas aeruginosa from infected burns.J Burn Care Rehabil2002; 23: 366–70.
32.
MerckollP., JonassenT.O., VadM.E., JeanssonS.L., MelbyK.K.Bacteria, biofilm and honey: a study of the effects of honey on ‘planktonic’ and biofilm-embedded chronic wound bacteria.Scand J Infect Dis2009; 41: 341–7.
33.
KwakmanP.H., te VeldeA.A., de BoerL., SpeijerD., Vandenbroucke-GraulsC.M., ZaatS.A.How honey kills bacteria.FASEB J2010; 24: 2576–82.
34.
KwakmanP.H., de BoerL., Ruyter-SpiraC.P., Creemers-MolenaarT., HelsperJ.P., Vandenbroucke-GraulsC.M.Medical-grade honey enriched with antimicrobial peptides has enhanced activity against antibiotic-resistant pathogens.Eur J Clin Microbiol Infect Dis2011; 30: 251–7.
35.
KwakmanP.H., van den AkkerJ.P., GüçlüA., AslamiH., BinnekadeJ.M., de BoerL.Medical-grade honey kills antibiotic-resistant bacteria in vitro and eradicates skin colonization.Clin Infect Dis2008; 46: 1677–82.
36.
MooreO.A., SmithL.A., CampbellF., SeersK., McQuayH.J., MooreR.A.Systematic review of the use of honey as a wound dressing.BMC Complement Altern Med2001; 1: 2.
37.
JohnsonD.W., van EpsC., MudgeD.W., WigginsK.J., ArmstrongK., HawleyC.M.Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients.J Am Soc Nephrol2005; 16: 1456–62.
38.
KwakmanP.H., MullerM.C., BinnekadeJ.M., van den AkkerJ.P., de BorgieC.A., SchultzM.J.Medical-grade honey does not reduce skin colonization at central venous catheter-insertion sites of critically ill patients: a randomized controlled trial.Crit Care2012; 16: R214.
39.
JohnsonD.W., BadveS.V., PascoeE.M., BellerE., CassA., ClarkC.Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial.Lancet Infect Dis2014; 14: 23–30.
40.
AtrottJ., HenleT.Methylglyoxal in Manuka honey—correlation with antibacterial properties.Czech J Food Sci2009; 27: S163–5.
41.
MavricE., WittmannS., BarthG., HenleT.Identification and quantification of methylglyoxal as the dominant antibacterial constituent of Manuka (Leptospermum scoparium) honeys from New Zealand.Mol Nutr Food Res2008; 52: 483–9.
42.
AdamsC.J., Manley-HarrisM., MolanP.The origin of methylglyoxal in New Zealand manuka (Leptospermum scoparium) honeyCarbohydr Res2009; 344: 1050–3.
43.
SchalkwijkC.G., ter WeeP.M., TeerlinkT.Reduced 1,2-dicarbonyl compounds in bicarbonate/lactate-buffered peritoneal dialysis (PD) fluids and PD fluids based on glucose polymers or amino acids.Perit Dial Int2000; 20: 796–8.
44.
VerbrughH.A., KeaneW.F., ConroyW.E., PetersonP.K.Bacterial growth and killing in chronic ambulatory peritoneal dialysis fluids.J Clin Microbiol1984; 20: 199–203.
Van EschS., KredietR.T., StruijkD.G.32-years of experience of peritoneal dialysis-related peritonitis in a university hospital.Perit Dial Int2014; 34: 162–70.
47.
SmitW., LangedijkM.J., SchoutenN., van den BergN., StruijkD.G., KredietR.T.A comparison between 1.36% and 3.86% glucose dialysis solution for the assessment of peritoneal membrane function.Perit Dial Int2000; 20: 734–41.
48.
SmitW., van EschS., StruijkD.G., KredietR.T.Free water transport in patients starting with peritoneal dialysis: a comparison between diabetic and non diabetic patients.Adv Perit Dial2004; 20: 13–7.
49.
GarredL.J., CanaudB., FarrellP.C.A simple kinetic model for assessing peritoneal mass transfer in chronic ambulatory peritoneal dialysis.ASAIO J1983; 6: 131–7.
50.
KredietR.T., Boeschoten, ZuijderhoudtF.M.J., StrackeeJ., AriszL.Simple assessment of the efficacy of peritoneal transport in continuous ambulatory peritoneal dialysis patients.Blood Purif1986; 4: 194–203.
